These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19761412)

  • 1. Neridronic acid for the treatment of bone metabolic diseases.
    Gatti D; Viapiana O; Idolazzi L; Fracassi E; Adami S
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1305-11. PubMed ID: 19761412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate use in conditions other than osteoporosis.
    Silverman SL
    Ann N Y Acad Sci; 2011 Feb; 1218():33-7. PubMed ID: 20946575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological therapy of Paget's and other metabolic bone diseases.
    Hosking D
    Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone.
    Cremers SC; Eekhoff ME; Den Hartigh J; Hamdy NA; Vermeij P; Papapoulos SE
    J Bone Miner Res; 2003 May; 18(5):868-75. PubMed ID: 12733726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
    D'Eufemia P; Finocchiaro R; Zambrano A; Tetti M; Ferrucci V; Celli M
    Biomed Pharmacother; 2007 May; 61(4):235-40. PubMed ID: 17275249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of neridronic acid on osteoclasts derived by physiological dual-cell cultures.
    Nicolin V; Bareggi R; Baldini G; Bortul R; Martinelli B; Narducci P
    Acta Histochem; 2007; 109(5):397-402. PubMed ID: 17574655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate treatment of pediatric bone disease.
    Speiser PW; Clarson CL; Eugster EA; Kemp SF; Radovick S; Rogol AD; Wilson TA;
    Pediatr Endocrinol Rev; 2005 Dec; 3(2):87-96. PubMed ID: 16361982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta.
    Gökşen D; Coker M; Darcan S; Köse T; Kara S
    Turk J Pediatr; 2006; 48(2):124-9. PubMed ID: 16848111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Paget's disease of bone.
    Langston AL; Ralston SH
    Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of osteogenesis imperfecta with bisphosphonates].
    Tau C
    Medicina (B Aires); 2007; 67(4):389-95. PubMed ID: 17891938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate treatment of bone disease.
    Shaw NJ; Bishop NJ
    Arch Dis Child; 2005 May; 90(5):494-9. PubMed ID: 15851432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report of implant placement in a patient with Paget's disease on bisphosphonate therapy.
    Pirih FQ; Zablotsky M; Cordell K; McCauley LK
    J Mich Dent Assoc; 2009 May; 91(5):38-43. PubMed ID: 19537656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative indications for bisphosphonate therapy.
    Landesberg R; Eisig S; Fennoy I; Siris E
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):27-34. PubMed ID: 19371812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?
    Rauch F; Glorieux FH
    Ann Med; 2005; 37(4):295-302. PubMed ID: 16019729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paget's disease of bone: presentation, extent and response to bisphosphonates.
    Wang LM; Au-Yeong ML; McKenna MJ
    Ir Med J; 2002 Sep; 95(8):244, 246. PubMed ID: 12405502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates in children with bone diseases.
    Plotkin H
    N Engl J Med; 2003 Nov; 349(21):2068-71; author reply 2068-71. PubMed ID: 14627793
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
    Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
    Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate use in the treatment of Paget's disease of the bone: analysis of claims in a large database.
    Dolgitser M; Stern L; Katz LM; Doyle JJ; Omar M; Seton M; Kahler KH
    Manag Care Interface; 2007 Feb; 20(2):33-40. PubMed ID: 17405580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with bisphosphonates in osteogenesis imperfecta.
    Glorieux FH
    Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.